The Evolving Role of Surgery in Melanoma

H&O What has been the traditional role of surgery in melanoma? VKS Surgery has long been the mainstay of treatment for all early-stage melanomas. We used […]

Are Vaccines Making a Comeback in Melanoma?

H&O What vaccines are approved for use in melanoma? JW We do not have any true vaccines that are approved and used for cancer at this […]

Adjuvant Therapy in High-Risk, Node-Negative Melanoma

H&O Which patients with high-risk, node-negative melanoma should receive adjuvant therapy? MR First, it is important to define what is meant by “high-risk,” or what the […]

Update on the DREAMseq Trial in Melanoma

H&O What was the impetus for the DREAMseq trial? MA In 2015, there were 2 different approaches to treating patients with metastatic BRAF-mutant melanoma, both of […]

New Evidence for Neoadjuvant Therapy in Advanced Melanoma

H&O What was the history behind the SWOG S1801 study that you presented at the most recent European Society for Medical Oncology congress? SP The benefits […]

Tumor-Infiltrating Lymphocyte Therapy in Metastatic Melanoma

H&O What options are available for patients with metastatic melanoma that does not respond or has stopped responding to checkpoint inhibition and BRAF/MEK-targeted agents? JC No […]

Nivolumab and Relatlimab as Frontline Therapy in Advanced Melanoma

H&O What makes the combination of nivolumab and relatlimab a good choice in advanced melanoma? NK We already have a wealth of data on monotherapy with […]

The Role of Triple Therapy in BRAF-Positive Melanoma

H&O How common is BRAF-positive melanoma? RS Melanoma is BRAF-positive in approximately 50% of cases that arise on the skin; 10% to 20% of cases that […]

Is Neoadjuvant Therapy Ready for Prime Time in Melanoma?

H&O What is the rationale for using neoadjuvant therapy in solid-organ cancers? MR Multimodality therapy has been shown to improve treatment outcomes vs surgery alone in […]

Update on Adjuvant Therapy in Late-Stage Resected Melanoma

H&O Which patients with melanoma are candidates for adjuvant therapy? AT Systemic adjuvant therapy that targets residual micrometastatic disease—which is the source of future melanoma relapse […]

The Role of Talimogene Laherparepvec (T-VEC) in the Age of Checkpoint Inhibitors

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Robert H. Andtbacka, MD, CM Associate Professor of Surgery University of Utah Huntsman Cancer […]

Adjuvant Treatment For Patients With Surgically Resected Advanced-Stage Melanoma

Kenneth F. Grossmann, MD, PhD Assistant Professor Huntsman Cancer Institute University of Utah Salt Lake City, Utah H&O What is the first step in treating patients […]

Neoadjuvant Therapy in Melanoma: The Fast Track to Critical New Answers

Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Ahmad A. Tarhini, MD, PhD Associate Professor of Medicine, Clinical, and Translational Science […]

Intermittent Dosing in Melanoma

Volume 13, Issue 6 June 2015 Martin McMahon, PhD Assistant Director of Professional Education Co-Leader, Developmental Therapeutics Program UCSF Helen Diller Family Comprehensive Cancer Center Efim […]